September 5, 2018
Recently, two TMC member institutions saw their cancer therapies gain the distinction of advancing to commercialization.
August 8, 2018
The researchers developed a novel therapy for cancer patients that harnesses the patient’s own immune system to fight cancer in a natural way. This therapy uses a ‘natural’ T cell response that does not require genetic engineering.
July 18, 2018
TapImmune Inc., Jacksonville's publicly traded developer of cancer-fighting immunotherapies, announced in May that it was merging with Minnesota-based Marker Therapeutics Inc., another developer of immunotherapies.
July 5, 2018
Company developing immunotherapy treatments for cancer up 139 percent this year.
June 15, 2018
TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments, begin a strategic alliance with Baylor College of Medicine and move to Houston. The stock has more than tripled since the announcement and rose more than 18 percent Friday.
June 2, 2018
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
May 31, 2018
History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
May 29, 2018
TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
May 23, 2018
Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
May 18, 2018
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.